Pulmonary Artery Hypoplasia in Neonates With Tetralogy of Fallot.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
15 08 2023
Historique:
received: 14 12 2022
revised: 27 04 2023
accepted: 22 05 2023
medline: 11 8 2023
pubmed: 10 8 2023
entrez: 9 8 2023
Statut: ppublish

Résumé

Neonates with symptomatic tetralogy of Fallot (sTOF) with hypoplastic pulmonary arteries (hPA) are considered high risk. Data are needed to inform the impact of hPA on outcomes, and the ideal management strategy. The objectives of this study were to quantify the impact of hPA on outcomes in neonates with sTOF and measure the impact of strategy on pulmonary artery (PA) growth in this population. Neonates with sTOF from 2005 to 2017 were reviewed from the Congenital Cardiac Research Collaborative. Criteria for hPA included a unilateral PA z score <-2.0 and contralateral PA z score <0. Primary outcome was mortality. Secondary outcomes included reintervention and PA growth. We included 542 neonates with sTOF, including 188 (35%) with hPA and 354 (65%) with normal PA, with median follow-up of 4.1 years. Median right and left hPA z scores were -2.19 (25th-75th percentile: -2.55 to -1.94) and -2.23 (25th-75th percentile: -2.64 to -1.91), respectively. Staged repair (vs primary TOF repair) was less common in the hPA cohort (36 vs 44%; P = 0.07). Survival was similar between groups (unadjusted P = 0.16; adjusted P = 0.25). Reintervention was more common in the hPA group (HR: 1.28; 95% CI: 1.01-1.63; P = 0.044); there was no difference after definitive repair (HR: 1.21; 95% CI: 0.93-1.58; P = 0.16). PA growth at 1 year was greater in the hPA cohort, particularly for the right PA (P < 0.001). Despite perception, the presence of hPA in neonates with sTOF conferred no increase in overall hazard of mortality or reintervention after definitive repair. PA growth was superior in the hPA cohort. These findings suggest that the presence of hPA does not adversely impact outcomes in sTOF.

Sections du résumé

BACKGROUND
Neonates with symptomatic tetralogy of Fallot (sTOF) with hypoplastic pulmonary arteries (hPA) are considered high risk. Data are needed to inform the impact of hPA on outcomes, and the ideal management strategy.
OBJECTIVES
The objectives of this study were to quantify the impact of hPA on outcomes in neonates with sTOF and measure the impact of strategy on pulmonary artery (PA) growth in this population.
METHODS
Neonates with sTOF from 2005 to 2017 were reviewed from the Congenital Cardiac Research Collaborative. Criteria for hPA included a unilateral PA z score <-2.0 and contralateral PA z score <0. Primary outcome was mortality. Secondary outcomes included reintervention and PA growth.
RESULTS
We included 542 neonates with sTOF, including 188 (35%) with hPA and 354 (65%) with normal PA, with median follow-up of 4.1 years. Median right and left hPA z scores were -2.19 (25th-75th percentile: -2.55 to -1.94) and -2.23 (25th-75th percentile: -2.64 to -1.91), respectively. Staged repair (vs primary TOF repair) was less common in the hPA cohort (36 vs 44%; P = 0.07). Survival was similar between groups (unadjusted P = 0.16; adjusted P = 0.25). Reintervention was more common in the hPA group (HR: 1.28; 95% CI: 1.01-1.63; P = 0.044); there was no difference after definitive repair (HR: 1.21; 95% CI: 0.93-1.58; P = 0.16). PA growth at 1 year was greater in the hPA cohort, particularly for the right PA (P < 0.001).
CONCLUSIONS
Despite perception, the presence of hPA in neonates with sTOF conferred no increase in overall hazard of mortality or reintervention after definitive repair. PA growth was superior in the hPA cohort. These findings suggest that the presence of hPA does not adversely impact outcomes in sTOF.

Identifiants

pubmed: 37558375
pii: S0735-1097(23)05907-7
doi: 10.1016/j.jacc.2023.05.051
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

615-627

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Christopher J Petit (CJ)

Division of Cardiology, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, New York, USA; Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia, USA. Electronic address: cjp2196@cumc.columbia.edu.

Andrew C Glatz (AC)

Division of Pediatric Cardiology, Perelman School of Medicine at the University of Pennsylvania, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Division of Pediatric Cardiology, Washington University School of Medicine and St Louis Children's Hospital, St Louis, Missouri, USA.

Andrew B Goldstone (AB)

Division of Cardiology, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, New York, USA.

Mark A Law (MA)

University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.

Jennifer C Romano (JC)

University of Michigan School of Medicine, Mott Children's Hospital, Ann Arbor, Michigan, USA.

Shiraz A Maskatia (SA)

University of California San Francisco School of Medicine, Benioff Children's Hospital, San Francisco, California, USA.

Paul J Chai (PJ)

Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

Jeffrey D Zampi (JD)

University of Michigan School of Medicine, Mott Children's Hospital, Ann Arbor, Michigan, USA.

Jeffery J Meadows (JJ)

University of California San Francisco School of Medicine, Benioff Children's Hospital, San Francisco, California, USA.

George T Nicholson (GT)

Division of Cardiology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Shabana Shahanavaz (S)

Division of Pediatric Cardiology, Washington University School of Medicine and St Louis Children's Hospital, St Louis, Missouri, USA; Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Athar M Qureshi (AM)

Baylor College of Medicine, Texas Children's Hospital, Waco, Texas, USA.

Courtney E McCracken (CE)

Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

Christopher E Mascio (CE)

Division of Pediatric Cardiology, Perelman School of Medicine at the University of Pennsylvania, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; University of West Virginia School of Medicine, Morgantown, West Virginia, USA.

Sarosh P Batlivala (SP)

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Ivor B Asztalos (IB)

Division of Pediatric Cardiology, Perelman School of Medicine at the University of Pennsylvania, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Steven J Healan (SJ)

Division of Cardiology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Justin D Smith (JD)

University of Michigan School of Medicine, Mott Children's Hospital, Ann Arbor, Michigan, USA.

Joelle A Pettus (JA)

Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

Asaad Beshish (A)

Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

James E B Raulston (JEB)

University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.

Krissie M Hock (KM)

University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.

Amy L Pajk (AL)

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Bryan H Goldstein (BH)

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA; University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH